Showing results (2061-2070 of 3,160) with videos related to
Sort By:
Pageof 316
Neuro-Oncology|January 17, 2013
Treatment, prognostic factors, and outcomes in spinal cord astrocytomasMohamad H Fakhreddine, Anita Mahajan, Marta Penas-Prado, et al.Neuro-Oncology|January 18, 2013
Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategiesNishant Verma, Matthew C Cowperthwaite, Mark G Burnett, et al.Neuro-Oncology|January 18, 2013
Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafishIn Hye Jung, Ga Lam Leem, Dawoon E Jung, et al.Neuro-Oncology|February 12, 2013
Imaging descriptors improve the predictive power of survival models for glioblastoma patientsMaciej Andrzej Mazurowski, Annick Desjardins, Jordan Milton MalofNeuro-Oncology|April 19, 2013
ZIP4 is a novel molecular marker for gliomaYi Lin, Yong Chen, Yongzhi Wang, et al.Neuro-Oncology|March 6, 2013
Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 casesShin-Ichi Miyatake, Motomasa Furuse, Shinji Kawabata, et al.Neuro-Oncology|February 16, 2013
Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomasTareq A Juratli, Mirko Peitzsch, Kathrin Geiger, et al.Neuro-Oncology|February 16, 2013
Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiformeAnna Rosati, Pietro Luigi Poliani, Alice Todeschini, et al.Neuro-Oncology|February 16, 2013
CRN2 enhances the invasiveness of glioblastoma cellsAnja Ziemann, Simon Hess, Ridhirama Bhuwania, et al.Neuro-Oncology|July 17, 2014
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trialBenedikt Wiestler, David Capper, Volker Hovestadt, et al.Pageof 316